CSS LLC’s Revolution Medicines RVMD Stock Holding History

CSS LLC’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.54M	Buy	29,600 +26,500	+855%	+$3.87M	0.22%	75
2026 Q1	$301K	Buy	3,100 +100	+3%	+$10.1K	0.01%	654
2025 Q4	$239K	Buy	+3,000	New	+$197K	0.01%	732

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

CSS LLC's RVMD Position: Q1 2026 in Review

CSS LLC sold out of Revolution Medicines (RVMD) in Q1 2026, closing a stake of 2,397 shares — an estimated $242K sold.

CSS LLC first reported a position in RVMD in Q4 2025 and held it in 1 quarter. The position peaked at $191K in Q4 2025. 514 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

CSS LLC reported no remaining Revolution Medicines position as of Q1 2026 after selling out during the quarter.
CSS LLC sold 2,397 Revolution Medicines shares in Q1 2026, an estimated $242K.
CSS LLC first reported a position in Revolution Medicines in Q4 2025 and held it in 1 quarter.
CSS LLC's Revolution Medicines position peaked at $191K in Q4 2025.
514 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on CSS LLC's 13F filing for Q1 2026, filed 15 May 2026.